Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eucalyptus globulus pollen is a non-standardized allergenic extract derived from the pollen of the Eucalyptus globulus tree. It is manufactured by Greer Laboratories, Inc. and marketed under the brand name "Bluegum Eucalyptus Pollen". [12] First approved in the U.S. in 1965, this biologic product is indicated for both the diagnosis and treatment of individuals with immediate hypersensitivity allergies to eucalyptus pollen. [7] The product works by interacting with the immune system to either diagnose sensitivity through skin testing or to desensitize patients via immunotherapy. [6] Allergic reactions to eucalyptus pollen can manifest as asthma, hay fever (rhinoconjunctivitis), and contact urticaria. It is administered as a solution through intradermal, percutaneous, or subcutaneous routes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Eucalyptus globulus pollen.